Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease

View ORCID ProfileSonia M Vallabh, View ORCID ProfileEric Vallabh Minikel, Victoria J Williams, Becky C Carlyle, Alison J McManus, Chase D Wennick, Anna Bolling, Bianca A Trombetta, David Urick, Chloe K Nobuhara, Jessica Gerber, Holly Duddy, Ingolf Lachmann, Christiane Stehmann, Steven J Collins, Kaj Blennow, Henrik Zetterberg, Steven E Arnold
doi: https://doi.org/10.1101/2019.12.13.19014217
Sonia M Vallabh
1Henry and Allison McCance Center for Brain Health, Massachusetts General Hospital, Boston, MA, 02114, USA
2Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA
3Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA
4Prion Alliance, Cambridge, MA, 02139, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sonia M Vallabh
  • For correspondence: searnold@mgh.harvard.edu svallabh@broadinstitute.org
Eric Vallabh Minikel
1Henry and Allison McCance Center for Brain Health, Massachusetts General Hospital, Boston, MA, 02114, USA
2Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA
3Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA
4Prion Alliance, Cambridge, MA, 02139, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eric Vallabh Minikel
Victoria J Williams
2Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Becky C Carlyle
2Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alison J McManus
2Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chase D Wennick
2Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Bolling
2Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bianca A Trombetta
2Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Urick
2Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chloe K Nobuhara
2Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Gerber
2Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Holly Duddy
2Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ingolf Lachmann
5AJ Roboscreen GmbH, Leipzig, 04129, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christiane Stehmann
6Australian National CJD Registry, University of Melbourne, Parkville, 3010, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven J Collins
6Australian National CJD Registry, University of Melbourne, Parkville, 3010, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kaj Blennow
7Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, S-431 80, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henrik Zetterberg
7Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, S-431 80, Sweden
8Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, S-431 80, Sweden
9UK Dementia Research Institute, University College London, London, WC1N 3BG, UK
10Department of Molecular Neuroscience, UCL Institute of Neurology, London, WC1N 3BG, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven E Arnold
1Henry and Allison McCance Center for Brain Health, Massachusetts General Hospital, Boston, MA, 02114, USA
2Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: searnold@mgh.harvard.edu svallabh@broadinstitute.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

BACKGROUND Fluid biomarkers are important in the development of therapeutics to delay or prevent prion disease, but have not been systematically evaluated in pre-symptomatic individuals at risk for genetic prion disease.

METHODS We recruited pre-symptomatic individuals with pathogenic mutations in the prion protein gene (PRNP; N=27) and matched controls (N=16), to donate cerebrospinal fluid (CSF) and blood at multiple timepoints to a cohort study at Massachusetts General Hospital. We quantified total prion protein (PrP) and real-time quaking-induced conversion (RT-QuIC) prion seeding activity in CSF, and the neuronal damage markers total tau (T-tau) and neurofilament light chain (NfL) in both CSF and plasma. We compared these markers cross-sectionally between mutation carriers and controls, evaluated short-term test-retest reliability over 2-4 months, and conducted a pilot longitudinal study over 10-20 months for a subset of participants.

FINDINGS CSF PrP levels were stable on test-retest with a mean coefficient of variation of 7% both over 2-4 months in N=29 participants and over 10-20 months in N=10 participants. RT-QuIC was negative in 22/23 mutation carriers. The sole individual with positive RT-QuIC seeding activity at two study visits had steady CSF PrP levels and slightly increased tau and NfL concentrations compared with others, though still within the normal range, and remained asymptomatic one year later. Overall, tau and NfL showed no significant differences between mutation carriers and controls in either CSF or plasma.

INTERPRETATION CSF PrP will be interpretable as a pharmacodynamic readout of the effects of a PrP-lowering therapeutic in pre-symptomatic individuals, and may serve as a surrogate biomarker in a “primary prevention” trial paradigm. In contrast, current markers of prion seeding activity and of neuronal damage do not reliably cross-sectionally distinguish mutation carriers from controls, arguing against the feasibility of a “secondary prevention” paradigm in which trials specifically recruit pre-symptomatic participants with prodromal evidence of pathology.

Competing Interest Statement

SEA has received honoraria and/or travel expenses for lectures from Abbvie, Biogen, EIP Pharma, Roche, and Sironax; has received fees for consulting and/or advisory boards from Athira, Biogen, Cassava, Cognito, Cortexyme, Sironax and vTv; and has received grant support from Abbvie, Amylyx, EIP Pharma and Merck. SMV has received speaking fees from Illumina and has received research support in the form of unrestricted charitable contributions from Charles River Laboratories and Ionis Pharmaceuticals. EVM has received research support in the form of unrestricted charitable contributions from Charles River Laboratories and Ionis Pharmaceuticals and has consulted for Deerfield Management and Guidepoint. KB holds the Torsten Söderberg Professorship, has served as a consultant or on advisory boards for Abcam, Axon, Biogen, Lilly, MagQu, Novartis and Roche Diagnostics, and is a cofounder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. HZ is a Wallenberg Academy Fellow, a cofounder of Brain Biomarker Solutions in Gothenburg A.B., a GU Ventures-based platform company at the University of Gothenburg, and has served on advisory boards for Roche Diagnostics, Wave, Samumed and CogRx.

Clinical Trial

N/A, this is not a clinical trial.

Funding Statement

This study was supported by Prion Alliance, CJD Foundation (the Michael H. Cole, Cheryl Molloy, José A. Piriz and Sonia E. Piriz, Jeffrey A. Smith, and Mercies in Disguise Memorial Grants), the Broad Institute (Broad Next Gen Fund and direct donations to Prions@Broad), the National Science Foundation (GRFP 2015214731 to SMV), the National Institutes of Health (F31 AI122592 to EVM and R21 TR003040 to SEA), and an anonymous organization. We thank Brendan Blumenstiel and Anna Koutoulas for assistance with DNA sequencing. We are grateful to all of the volunteers who participated in this research study.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

R source code for this study is available in a public repository: https://github.com/ericminikel/mgh_prnp_fluid_biomarkers De-identified data will be made available to qualified investigators upon request.

https://github.com/ericminikel/mgh_prnp_fluid_biomarkers

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted December 15, 2019.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease
Sonia M Vallabh, Eric Vallabh Minikel, Victoria J Williams, Becky C Carlyle, Alison J McManus, Chase D Wennick, Anna Bolling, Bianca A Trombetta, David Urick, Chloe K Nobuhara, Jessica Gerber, Holly Duddy, Ingolf Lachmann, Christiane Stehmann, Steven J Collins, Kaj Blennow, Henrik Zetterberg, Steven E Arnold
medRxiv 2019.12.13.19014217; doi: https://doi.org/10.1101/2019.12.13.19014217
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease
Sonia M Vallabh, Eric Vallabh Minikel, Victoria J Williams, Becky C Carlyle, Alison J McManus, Chase D Wennick, Anna Bolling, Bianca A Trombetta, David Urick, Chloe K Nobuhara, Jessica Gerber, Holly Duddy, Ingolf Lachmann, Christiane Stehmann, Steven J Collins, Kaj Blennow, Henrik Zetterberg, Steven E Arnold
medRxiv 2019.12.13.19014217; doi: https://doi.org/10.1101/2019.12.13.19014217

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (434)
  • Anesthesia (99)
  • Cardiovascular Medicine (948)
  • Dentistry and Oral Medicine (178)
  • Dermatology (110)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (422)
  • Epidemiology (8989)
  • Forensic Medicine (4)
  • Gastroenterology (420)
  • Genetic and Genomic Medicine (1959)
  • Geriatric Medicine (190)
  • Health Economics (402)
  • Health Informatics (1329)
  • Health Policy (660)
  • Health Systems and Quality Improvement (519)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10809)
  • Intensive Care and Critical Care Medicine (575)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (222)
  • Neurology (1830)
  • Nursing (110)
  • Nutrition (274)
  • Obstetrics and Gynecology (353)
  • Occupational and Environmental Health (470)
  • Oncology (999)
  • Ophthalmology (298)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (580)
  • Pharmacology and Therapeutics (276)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1904)
  • Public and Global Health (4123)
  • Radiology and Imaging (676)
  • Rehabilitation Medicine and Physical Therapy (368)
  • Respiratory Medicine (549)
  • Rheumatology (225)
  • Sexual and Reproductive Health (191)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (109)
  • Urology (81)